Does Gateway Health Plan Cover Cialis?

What Is Gateway Health Plan and Who Does It Cover?

Gateway Health Plan is a Pittsburgh-based managed care organization that administers Medicaid, Medicare Advantage, and commercial health insurance plans primarily in Pennsylvania. The plan serves roughly 350,000 members across its product lines, which means the formulary and coverage rules vary substantially from one product to the next. A member enrolled in Gateway's Pennsylvania Medicaid product operates under a completely different drug benefit structure than a member in a Gateway Medicare Advantage plan or an employer-sponsored commercial product.

The FDA approved tadalafil (Cialis) on 1 October 2003 for erectile dysfunction, and the agency later approved a 5 mg daily dose for BPH and a combination ED plus BPH indication. A separate high-dose tadalafil formulation marketed as Adcirca carries an FDA approval for pulmonary arterial hypertension. Because the drug carries multiple approved indications, the coverage determination at any insurer including Gateway is indication-specific, not drug-specific. That distinction matters when building a prior authorization case.

Identifying your exact Gateway product on your insurance card is the first step. Call the member services number on the back of the card and ask specifically whether your plan is a Medicaid managed care plan, a Medicare Advantage plan, or a commercial/employer plan. Each category follows different legal rules about PDE5 inhibitor coverage.

Federal and State Rules That Shape Medicaid Coverage of Erectile Dysfunction Drugs

Federal law is the single largest barrier to Cialis coverage on Medicaid-based plans. The Social Security Act at Section 1927(d)(2) explicitly lists agents used for erectile dysfunction as an excluded drug category for Medicaid coverage. The Centers for Medicare and Medicaid Services (CMS) confirms this exclusion in its Medicaid drug policy guidance. Because Gateway's Pennsylvania Medicaid product must comply with federal Medicaid statute, the plan cannot cover Cialis or tadalafil when the diagnosis code on the prescription is erectile dysfunction (ICD-10 N52.x).

Pennsylvania's own Medicaid rules do not override the federal exclusion. The Pennsylvania Department of Human Services follows standard federal guidance on excluded drug classes. The state's fee-for-service preferred drug list, which gateway Medicaid plans use as a reference, reflects this restriction.

The exception that opens a coverage pathway: tadalafil 5 mg prescribed specifically for BPH (ICD-10 N40.x) does not fall under the ED exclusion. The American Urological Association 2021 BPH guideline recommends PDE5 inhibitors, including tadalafil 5 mg daily, as a monotherapy option for lower urinary tract symptoms attributed to BPH, particularly in men who also have erectile dysfunction. When a prescriber documents the BPH indication clearly and the diagnosis code matches, the Medicaid exclusion for ED drugs does not automatically apply. Coverage approval for BPH-indicated tadalafil on a Medicaid plan still requires prior authorization, but it is a legitimate and often successful pathway.

How Gateway Medicare Advantage Plans Handle Cialis

Medicare Part D, which governs prescription drug coverage in Medicare Advantage plans including Gateway's, operates under a separate legal framework. CMS regulations at 42 CFR 423.100 list erectile dysfunction agents as a protected-class exclusion from required Part D formulary inclusion, meaning Part D sponsors are not required to cover ED drugs but may choose to do so. Gateway Medicare Advantage plans have discretion here. Some gateway Medicare Advantage plan formularies include generic tadalafil at a high tier (Tier 3 or Tier 4) for BPH and require prior authorization. Brand-name Cialis is almost never covered on Medicare Advantage formularies because generic tadalafil became available in the United States after the patent expiration in 2018.

FDA records show that multiple manufacturers received approval for generic tadalafil tablets starting in 2018, which drove the retail price from over $400 per month to under $30 per month. Gateway Medicare Advantage formulary decisions now focus almost entirely on the generic. Check your plan's Evidence of Coverage document, specifically the drug list appendix, to see whether tadalafil (not Cialis) appears and at what tier. If it appears only for BPH (diagnosis-specific coverage), your physician must submit documentation confirming the BPH indication.

For men covered under Medicare, the FDA-approved tadalafil 5 mg once-daily dosing studied in the key trial published in the Journal of Urology showed statistically significant improvement in International Prostate Symptom Score (IPSS) versus placebo (P<0.001) over 12 weeks, which gives prescribers strong clinical evidence to attach to a prior authorization request.

Coverage Rules on Gateway Commercial and Employer Plans

Commercial plans sold through employers or the individual market give Gateway more flexibility than Medicaid law allows. These plans must still comply with state insurance regulations and ACA essential health benefit requirements, but ED drugs are not an EHB category, so coverage is entirely at the plan's discretion.

A 2022 JAMA Internal Medicine analysis found that among large employer-sponsored health plans, approximately 43% included some PDE5 inhibitor coverage, though benefit designs varied widely. Gateway commercial plan formularies generally place generic tadalafil in Tier 2 or Tier 3 with prior authorization. Step therapy is common: the plan may require a documented trial of sildenafil (generic Viagra) of at least 30 days before approving tadalafil. This is a practical hurdle, but not an insurmountable one, especially for men who have a documented clinical reason for preferring tadalafil's 36-hour duration of action over sildenafil's 4-to-6-hour window.

The Endocrine Society's 2010 clinical practice guideline on male sexual dysfunction, updated in guidance through 2019, states that PDE5 inhibitors are first-line pharmacotherapy for erectile dysfunction in the absence of contraindications, citing response rates of 60 to 70 percent for tadalafil across major trials. Documenting this guideline recommendation in a prior authorization letter strengthens the clinical case.

For commercial plans, also check whether your employer's benefits summary includes a "lifestyle drug" exclusion. Some plans carve out ED drugs under this label. If your plan has such an exclusion and your only indication is ED (not BPH), appeals based on medical necessity are less likely to succeed and alternative cost strategies become more relevant.

Prior Authorization: What Gateway Typically Requires

Prior authorization for tadalafil on Gateway plans, regardless of product type, generally requires five elements. The prescriber must document the confirmed diagnosis (BPH, ED, or both) with the correct ICD-10 code. A clinical note summarizing symptom severity supports the request. For commercial plans requiring step therapy, the record must show that sildenafil was tried and either failed or caused intolerable adverse effects. Any contraindication to sildenafil (such as drug-drug interaction with nitrates or certain alpha-blockers) must be noted. Finally, relevant comorbidities including diabetes, cardiovascular disease, or prostatectomy history contextualize the prescription medically.

Erectile dysfunction affects approximately 52% of men between ages 40 and 70 based on the Massachusetts Male Aging Study, with prevalence rising sharply with age and metabolic disease burden. Citing population-level prevalence and the patient's specific risk factors in the prior authorization narrative helps justify medical necessity rather than framing the prescription as elective.

Type 2 diabetes doubles the risk of ED compared with the general male population, according to a meta-analysis of 145 studies published in Diabetic Medicine. For a Gateway member with diabetes-related ED, this evidence supports the argument that treatment is management of a disease complication, not a lifestyle choice.

A five-step prior authorization framework for Gateway tadalafil requests:

1. Confirm the correct ICD-10 code: N40.1 (BPH with LUTS) or N52.9 (ED, unspecified) or N52.01 (ED due to arterial insufficiency).
2. Attach the AUA guideline citation supporting PDE5 inhibitor use for the documented indication.
3. Include lab results (fasting glucose, HbA1c, testosterone) that document contributing comorbidities.
4. For step-therapy plans, provide a dated pharmacy dispensing record showing sildenafil was dispensed and a clinical note stating why it was inadequate.
5. Request an expedited determination if the treating physician certifies that the standard 30-day timeline would adversely affect the patient's condition.

What Happens When Gateway Denies Coverage

A denial from Gateway does not close the door. Pennsylvania law and federal Medicaid/Medicare rules provide structured appeal rights. For Medicaid members, the first step is a plan-level appeal filed within 30 days of the denial notice. If that fails, a State Fair Hearing before an administrative law judge is available. The Pennsylvania Department of Human Services outlines the fair hearing process in detail, including the right to continued benefits during the hearing for ongoing treatments.

For Medicare Advantage members, the appeals ladder runs from plan-level redetermination to Qualified Independent Contractor (QIC) review to an Administrative Law Judge hearing to the Medicare Appeals Council and, if necessary, federal district court. CMS publishes the Medicare appeals process timeline online, with QIC decisions required within 60 days for standard redeterminations.

A 2021 OIG report found that Medicare Advantage plans denied 13% of prior authorization requests that met Medicare coverage criteria, and that 75% of appealed denials were overturned on internal appeal. That overturn rate matters. Filing an appeal with complete documentation is worth the effort.

For commercial plan denials, an external review by an independent organization is available under ACA rules when the internal appeal fails. Pennsylvania's Insurance Department oversees external reviews for state-regulated plans.

Alternatives When Coverage Is Denied

Generic tadalafil is genuinely affordable without insurance. At GoodRx pricing as of early 2025, a 30-day supply of tadalafil 5 mg daily costs $15 to $28 at major retail pharmacies including Walmart, Costco, and CVS. FDA bioequivalence standards require generic tadalafil to deliver the same active ingredient at the same dose within the same absorption range as brand Cialis, confirmed through the FDA's Orange Book. The clinical outcome is identical to brand-name Cialis.

Manufacturer patient assistance programs for brand-name Cialis exist but are primarily relevant for patients who cannot take the generic due to a specific formulation issue, which is uncommon. Eli Lilly's patient assistance program is available through NeedyMeds and through Lilly's own Insulin Value Program infrastructure, though tadalafil assistance is less broadly marketed than the diabetes offerings.

Sildenafil 100 mg tablets, which a prescriber can instruct the patient to split into 50 mg doses, cost under $10 per month at some pharmacies and carry the same FDA indication for erectile dysfunction. For patients without a clinical preference for tadalafil's longer duration, sildenafil is a pharmacologically equivalent alternative at a fraction of the cost.

Telehealth platforms including HealthRX allow board-certified physicians to evaluate ED and BPH clinically, write a tadalafil prescription with the correct diagnosis coding, and generate prior authorization documentation designed to meet Gateway's specific formulary criteria.

The Role of Testosterone in ED Coverage Decisions

Low testosterone (hypogonadism) is a recognized contributor to ED and BPH symptom burden. The American Urological Association defines hypogonadism as a total morning testosterone below 300 ng/dL on two separate morning measurements, confirmed by a reliable assay. When hypogonadism is diagnosed and documented alongside ED, the coverage argument shifts from lifestyle drug to treatment of a diagnosed endocrine condition. Some Gateway commercial plan formularies cover PDE5 inhibitors more readily when the underlying hormonal deficit is also being treated.

A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=140) found that testosterone replacement combined with PDE5 inhibitor therapy produced significantly greater improvement in erectile function scores than PDE5 inhibitor alone in hypogonadal men (P<0.001). Documenting this comorbidity in the prior authorization request adds clinical weight and may shift the coverage decision.

Special Populations: Post-Prostatectomy and Cardiovascular Disease

Men who develop ED following radical prostatectomy for prostate cancer occupy a distinct clinical position. The AUA/ASTRO/SUO Guideline on Clinically Localized Prostate Cancer recommends penile rehabilitation with PDE5 inhibitors following nerve-sparing prostatectomy, citing evidence that early use preserves erectile function recovery. When a prescriber documents post-prostatectomy ED with a rehabilitation intent, the framing is oncologic recovery, not elective enhancement. Gateway commercial plans are more likely to approve prior authorization under this framing.

Cardiovascular comorbidity also shapes the clinical picture. The Princeton Consensus Panel III guidelines on sexual activity in cardiovascular disease, published in the Mayo Clinic Proceedings, classify most stable cardiovascular patients as low-risk and appropriate for PDE5 inhibitor therapy. Providing this risk stratification in documentation reassures the medical reviewer that the prescription is clinically indicated and safe.

PDE5 inhibitors are contraindicated with nitrates due to risk of severe hypotension, as noted in the FDA prescribing information for tadalafil. Any prior authorization template must confirm the absence of nitrate use to satisfy Gateway's safety screening criteria.

Pulmonary Arterial Hypertension: A Covered Indication on Most Plans

Tadalafil 40 mg daily (branded as Adcirca) carries an FDA approval for pulmonary arterial hypertension (PAH). The PHIRST trial (N=405) demonstrated that tadalafil 40 mg reduced the risk of clinical worsening events by 68% versus placebo over 16 weeks in patients with PAH. This indication is treated as a serious medical condition, not a lifestyle drug, and is covered on nearly all Gateway plan types including Medicaid when the diagnosis is properly documented. The drug is the same molecule as Cialis; the indication and dose differ.

If a patient carries a dual diagnosis of PAH and ED, the prescribing approach requires coordination between the treating pulmonologist and urologist to avoid dosing conflicts.

How to Confirm Your Specific Coverage Before the Prescription Is Written

Calling Gateway member services after confirming your plan type is faster and more reliable than reading the formulary PDF alone. Ask three specific questions: Does your formulary include tadalafil? What is the tier and the copay? Does the coverage require a specific ICD-10 code (BPH versus ED)?

CMS requires all Medicare Part D plan sponsors to maintain an online formulary lookup tool updated within 30 days of any change. Gateway's Medicare Advantage formulary tool is accessible on the plan's member portal. Medicaid formulary information is available through Pennsylvania's ePACES system.

Your prescribing physician's office can run a real-time benefits check (RTBC) through most electronic health record systems, which returns the exact copay and PA requirement at the point of prescribing. Requesting this check before the prescription is sent to the pharmacy eliminates surprises at the counter.